Compare LEXX & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEXX | VNRX |
|---|---|---|
| Founded | 2004 | N/A |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7M | 7.2M |
| IPO Year | 2011 | 2012 |
| Metric | LEXX | VNRX |
|---|---|---|
| Price | $3.08 | $0.17 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $13.62 |
| AVG Volume (30 Days) | 58.3K | ★ 1.3M |
| Earning Date | 11-27-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | $705,923.00 | ★ $1,727,384.00 |
| Revenue This Year | N/A | $57.67 |
| Revenue Next Year | $6,915.00 | $240.52 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 52.05 | 40.04 |
| 52 Week Low | $0.35 | $0.13 |
| 52 Week High | $21.60 | $3.26 |
| Indicator | LEXX | VNRX |
|---|---|---|
| Relative Strength Index (RSI) | 41.70 | 26.92 |
| Support Level | $2.67 | $0.15 |
| Resistance Level | $3.90 | $0.18 |
| Average True Range (ATR) | 0.45 | 0.02 |
| MACD | 0.19 | 0.01 |
| Stochastic Oscillator | 43.54 | 19.34 |
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on diagnostics and monitoring.